What the FDA labels say about taking them together
Lithium and sargramostim
Sargramostim's FDA label of December 6, 2024 names lithium in its drug interactions section; the lithium labels PlainMeds reads (4) do not name sargramostim.
Check it at the source: the lithium FDA label on DailyMed (effective December 23, 2025, Glenmark Pharmaceuticals Inc., USA); the sargramostim FDA label on DailyMed (effective December 6, 2024, Partner Therapeutics, Inc.).
What does the lithium label say about sargramostim?
Lithium's label (effective December 23, 2025) and its 3 other brand-application labels do not name sargramostim in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lithium Carbonate), Glenmark Pharmaceuticals Inc., USA, effective December 23, 2025 (SPL set 63b3790f-a9b5-47f4-bae1-ddf8b43c13c1), via openFDA; the full label on DailyMed
What does the sargramostim label say about lithium?
Sargramostim label, drug interactionsDRUG INTERACTIONS Use with caution in patients receiving drugs that may potentiate LEUKINE's myeloproliferative effects, such as lithium and corticosteroids.
Source: FDA drug label (Leukine), BLA103362 (Berlex Labs), as published by Partner Therapeutics, Inc., effective December 6, 2024 (SPL set bb9a3820-f31a-4dd9-bef4-97094c01a398), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lithium | Sargramostim | |
|---|---|---|
| Labeled for | Bipolar disorder | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per capsule 300 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once